SIMEK, Matej, Martina HERMANNOVA, Daniela SMEJKALOVA, Tereza FOGLOVA, Karel SOUČEK, Lucia BINO and Vladimir VELEBNY. LC-MS/MS study of in vivo fate of hyaluronan polymeric micelles carrying doxorubicin. Carbohydrate Polymers. Oxford: ELSEVIER SCI LTD, 2019, vol. 209, APR 1 2019, p. 181-189. ISSN 0144-8617. Available from: https://dx.doi.org/10.1016/j.carbpol.2018.12.104.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name LC-MS/MS study of in vivo fate of hyaluronan polymeric micelles carrying doxorubicin
Authors SIMEK, Matej, Martina HERMANNOVA (guarantor), Daniela SMEJKALOVA, Tereza FOGLOVA, Karel SOUČEK (203 Czech Republic, belonging to the institution), Lucia BINO and Vladimir VELEBNY.
Edition Carbohydrate Polymers, Oxford, ELSEVIER SCI LTD, 2019, 0144-8617.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10400 1.4 Chemical sciences
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.182
RIV identification code RIV/00216224:14310/19:00113513
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1016/j.carbpol.2018.12.104
UT WoS 000457546200018
Keywords in English Hyaluronan; Doxorubicin; Polymeric micelles; Biodistribution; Pharmacokinetics
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 2/4/2020 12:42.
Abstract
A better understanding of in vivo behavior of nanocarriers is necessary for further improvement in their development. Here we present a novel approach, where both the matrix and the drug can be analyzed by LC-MS/MS after one sample handling. The developed method was applied for the comparison of pharmacokinetic profile of free and encapsulated doxorubicin (DOX) in oleyl hyaluronan (HA-C18:1) polymeric micelles. The results indicated that nanocarriers were rapidly dissociated upon in vivo administration. Despite this fact, the administration of encapsulated DOX led to its longer circulation time and enhanced tumor targeting. This effect was not observed injecting blank HA-C18:1 micelles followed by unencapsulated DOX. Biodistribution studies and molecular weight estimation of the carrier matrix indicated relatively high stability of HA-C18:1 ester bond in bloodstream and complete elimination of the derivative within 72 h. The proposed methodology provides a novel strategy to elucidate the pharmacokinetic behavior of polysaccharide-based drug delivery systems.
PrintDisplayed: 25/5/2024 21:50